It’s a familiar scenario: a product failure or other high-profile event imperils public safety, prompting new, more stringent government regulations. The refreshed and timely medical device regulation and in vitro diagnostic regulation create the improved opportunity to plan and avoid recalls:
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 April 2026 An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.